Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.

Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M.

Eur J Cancer. 2020 Mar 25;130:155-167. doi: 10.1016/j.ejca.2020.02.023. [Epub ahead of print]

PMID:
32220780
2.

Clinical significance of ROS1 5' deletions detected by FISH and response to crizotinib.

Dall'Olio FG, Lamberti G, Capizzi E, Gruppioni E, Sperandi F, Altimari A, Giunchi F, Fiorentino M, Ardizzoni A.

Ann Oncol. 2019 Apr;30 Suppl 2:ii54-ii55. doi: 10.1093/annonc/mdz063.044. No abstract available.

3.

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.

Di Federico A, Filippini DM, Dall'Olio FG, Conci N, Minari R, Tiseo M, Ardizzoni A.

Clin Cancer Res. 2020 Jan 15;26(2):518-519. doi: 10.1158/1078-0432.CCR-19-2441. No abstract available.

PMID:
31941684
4.

Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.

Gelsomino F, Di Federico A, Filippini DM, Dall'Olio FG, Lamberti G, Sperandi F, Balacchi C, Brocchi S, Ardizzoni A.

Clin Lung Cancer. 2020 Mar;21(2):e45-e48. doi: 10.1016/j.cllc.2019.11.011. Epub 2019 Nov 20. No abstract available.

PMID:
31902695
5.

Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors.

Dall'Olio FG, Di Nunno V, Massari F.

J Clin Oncol. 2020 Jan 1;38(1):105-106. doi: 10.1200/JCO.19.01728. Epub 2019 Nov 1. No abstract available.

PMID:
31675246
6.

Clinical significance of ROS1 5' deletions in non-small cell lung cancer.

Capizzi E, Dall'Olio FG, Gruppioni E, Sperandi F, Altimari A, Giunchi F, Fiorentino M, Ardizzoni A.

Lung Cancer. 2019 Sep;135:88-91. doi: 10.1016/j.lungcan.2019.07.017. Epub 2019 Jul 17.

PMID:
31447007
7.

Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect.

Nuvola G, Dall'Olio FG, Melotti B, Sperandi F, Ardizzoni A.

J Thorac Oncol. 2019 Jul;14(7):e145-e146. doi: 10.1016/j.jtho.2019.02.027. No abstract available.

PMID:
31235038
8.

Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression.

Cavalleri T, Bianchi P, Basso G, Celesti G, Grizzi F, Bossi P, Greco L, Pitrone C, Valtorta E, Mauri G, Truini M, Dall'Olio FG, Brandi G, Sartore-Bianchi A, Ricciardiello L, Torri V, Rimassa L, Siena S, Mantovani A, Malesci A, Laghi L; Alleanza contro il Cancro (ACC) Colorectal Cancer Working Group.

Cancer Immunol Res. 2019 May;7(5):751-758. doi: 10.1158/2326-6066.CIR-18-0661. Epub 2019 Feb 25.

PMID:
30804005
9.

Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding.

Dall'Olio FG, Sperandi F, Rihawi K, Gargiulo M, Melotti B, Brocchi S, Gelsomino F, Ardizzoni A.

J Thorac Oncol. 2018 Dec;13(12):e247-e248. doi: 10.1016/j.jtho.2018.07.013. No abstract available.

10.

Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?

Dall'Olio FG, Brocchi S, Massucci M, Sperandi F, Melotti B, Ardizzoni A.

Eur J Cancer. 2018 May;95:127-129. doi: 10.1016/j.ejca.2018.02.020. Epub 2018 Mar 21. No abstract available.

PMID:
29573943
11.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M-Positive Non-Small Cell Lung Adenocarcinoma.

Dall'Olio FG, Ruatta C, Melotti B, Sperandi F, Ciardella AP, Ardizzoni A.

J Thorac Oncol. 2017 Oct;12(10):e165-e167. doi: 10.1016/j.jtho.2017.06.001. No abstract available.

12.

Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis.

Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall'Olio FG, Barbera MA, Pantaleo MA, Biasco G.

World J Gastroenterol. 2016 Jan 14;22(2):519-33. doi: 10.3748/wjg.v22.i2.519. Review.

13.

The 'surprise' question in advanced cancer patients: A prospective study among general practitioners.

Moroni M, Zocchi D, Bolognesi D, Abernethy A, Rondelli R, Savorani G, Salera M, Dall'Olio FG, Galli G, Biasco G; on behalf of the SUQ-P group.

Palliat Med. 2014 Jul;28(7):959-964. Epub 2014 Mar 24.

PMID:
24662237

Supplemental Content

Loading ...
Support Center